In this first episode of a 2-part series, expert faculty provide key insights and take questions from healthcare professionals on aspects of influenza management in high-risk patients during the COVID-19 pandemic. Topics include influenza diagnostic, prevention, and antiviral treatment strategies.
After completing this activity, participants should be better able to:
- Identify patient populations for whom baloxavir is an appropriate agent for influenza post-exposure prophylaxis
- Summarize resources for determining local and national influenza prevalence
- Discern strategies for influenza treatment in patients with influenza and COVID-19 coinfection
Physicians, NPs, and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AMA Credit Designation
Practicing Clinicians Exchange designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation
NP course advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, CaliforniaNursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until August 14, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Lawrence Herman, DMSc, MPA, PA-C, University of Lynchburg, Lynchburg, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by an educational grant from Genentech.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Herman: fees for non-CME/CE services: Novo Nordisk.
Dr Zivin-Tutela has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose except Dr Herman as noted above.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 100%.
The estimated time to complete this activity is 0.25 hours.
Release date: August 15, 2021
Expiration date: August 14, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 102221C-FP1